Enforcement Report - Week of February 24, 2021
Enforcement Report - Week of December 30, 2020
Enforcement Report - Week of July 22, 2020
Auryxia (Ferric Citrate) : Keryx Biopharma vs. Mylan Pharma
Auryxia (Ferric Citrate) : Keryx Biopharmaceuticals vs. Teva Pharmaceuticals
The merger of Akebia and Keryx is subject to the satisfaction of various closing conditions, including approval by shareholders of both companies. The special meetings of Akebia and Keryx shareholders to vote on matters relating to the proposed merger have been scheduled for December 11, 2018. Holders of record of Akebia and Keryx common stock as of 5:00 p.m. Eastern Time on October 22, 2018, will be entitled to vote at their respective special meetings.
Wolf Popper LLP is investigating claims on behalf of investors in Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), concerning the proposed acquisition of Keryx by Akebia Therapeutics, Inc. (NASDAQ: AKBA). Under the terms of the agreement, shareholders of Keryx common stock will receive 0.37433 common shares of Akebia for each share of Keryx they own. The offer value of $3.89 per share is below Keryx's 52-week high and average stock prices of $8.25 and $5.59 per share, respectively, and is also significantly below at least one analyst price target of $9.00 per share. Keryx's shareholders seeking more information about the transaction or Wolf Popper's investigation can contact Carl Stine at (212) 759-4600 or cstine@wolfpopper.com.
Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) stockholders concerning the proposed acquisition of the company by Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc and Keryx Biopharmaceuticals have announced that the companies are set to merge, creating a fully integrated biopharmaceutical giant in an all-stock merger.
Akebia Therapeutics is set to merge with Keryx Biopharmaceuticals. The combined company will own potentially complementary kidney disease drugs and a sales force to promote them, setting it up to fend off competition from rivals including FibroGen and GlaxoSmithKline.